JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 100 filers reported holding JOUNCE THERAPEUTICS INC in Q4 2019. The put-call ratio across all filers is 0.88 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2020 | $76,000 | -13.6% | 10,816 | 0.0% | 0.01% | -22.2% |
| Q3 2020 | $88,000 | +17.3% | 10,816 | 0.0% | 0.01% | +12.5% |
| Q2 2020 | $75,000 | +47.1% | 10,816 | 0.0% | 0.01% | +14.3% |
| Q1 2020 | $51,000 | -45.7% | 10,816 | 0.0% | 0.01% | -22.2% |
| Q4 2019 | $94,000 | +161.1% | 10,816 | 0.0% | 0.01% | +125.0% |
| Q3 2019 | $36,000 | -33.3% | 10,816 | 0.0% | 0.00% | -33.3% |
| Q2 2019 | $54,000 | -19.4% | 10,816 | 0.0% | 0.01% | -14.3% |
| Q1 2019 | $67,000 | +86.1% | 10,816 | 0.0% | 0.01% | +75.0% |
| Q4 2018 | $36,000 | -48.6% | 10,816 | 0.0% | 0.00% | -42.9% |
| Q3 2018 | $70,000 | -15.7% | 10,816 | 0.0% | 0.01% | -22.2% |
| Q2 2018 | $83,000 | -66.3% | 10,816 | -1.8% | 0.01% | -69.0% |
| Q1 2018 | $246,000 | -55.1% | 11,016 | -74.4% | 0.03% | -52.5% |
| Q4 2017 | $548,000 | -18.2% | 43,016 | 0.0% | 0.06% | -22.8% |
| Q3 2017 | $670,000 | – | 43,016 | – | 0.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 9,200,349 | $64,402,000 | 44.86% |
| TRV GP III, LLC | 3,048,780 | $21,342,000 | 1.83% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 406,665 | $2,847,000 | 1.65% |
| Sofinnova Investments, Inc. | 925,280 | $6,477,000 | 0.39% |
| Omega Fund Management, LLC | 334,965 | $2,345,000 | 0.35% |
| Yorktown Management & Research Co Inc | 49,200 | $344,000 | 0.31% |
| Woodline Partners LP | 940,902 | $6,586,000 | 0.18% |
| HUSSMAN STRATEGIC ADVISORS, INC. | 51,000 | $357,000 | 0.09% |
| HORIZON FINANCIAL SERVICES, LLC | 12,005 | $84,000 | 0.08% |
| Gyon Technologies Capital Management, LP | 26,893 | $188,000 | 0.06% |